2017
DOI: 10.1155/2017/8197035
|View full text |Cite
|
Sign up to set email alerts
|

Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution

Abstract: Neostigmine has been traditionally used as the agent of choice to reverse Neuromuscular Blockade (NMB) after muscle paralysis during general anesthesia. However, the use of neostigmine has not been without untoward events. Sugammadex is a novel drug that selectively binds to aminosteroid nondepolarizing muscle relaxants and reverses even a deep level of NMB. Controversy exists regarding the optimal dose of sugammadex that is effective in reversing the NMB after the incomplete reversal with neostigmine and glyc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 14 publications
0
8
0
Order By: Relevance
“…Since this is the first clinical trial that proposes, as its primary endpoint, a relative reduction of 30% in the incidence of residual curarization, the necessary sample size has been calculated using the statistical software Epi Info (version 7). This analysis shows that at least 30 patients per group will be necessary, considering that in 5% of subjects TF is not valuable [ 22 , 23 ], and expecting 23–25% of residual curarization with neostigmine 30 min after the extubation vs. 2–4% after the administration of sugammadex (with a 95% confidence interval (CI) and a power of 80%, and assuming equal variance between the two groups). For the secondary outcome, the number needed to treat has been calculated with a CI of 95%.…”
Section: Methodsmentioning
confidence: 99%
“…Since this is the first clinical trial that proposes, as its primary endpoint, a relative reduction of 30% in the incidence of residual curarization, the necessary sample size has been calculated using the statistical software Epi Info (version 7). This analysis shows that at least 30 patients per group will be necessary, considering that in 5% of subjects TF is not valuable [ 22 , 23 ], and expecting 23–25% of residual curarization with neostigmine 30 min after the extubation vs. 2–4% after the administration of sugammadex (with a 95% confidence interval (CI) and a power of 80%, and assuming equal variance between the two groups). For the secondary outcome, the number needed to treat has been calculated with a CI of 95%.…”
Section: Methodsmentioning
confidence: 99%
“…Mean of residual blockage without reversal 72% timization of surgical conditions. However, there are several risks in the use of neuromuscular blocking agents, the most critical being inadequate recovery of neuromuscular function, leading to complications due to upper airway muscle weakness [11]. Accordingly, reversible agents such as acetylcholinesterase inhibitors and Sugamadex are used to antagonize non-depolarizing muscle relaxant effects and prevent complications due to residual curarization, as observed in this research.…”
Section: Overall Average 89%mentioning
confidence: 89%
“…It is conventionally used for reversal of neuromuscular block induced by nondepolarizing neuromuscular blocking drugs at the end of surgery. [6] The use of neostigmine is known to be safe and effective for most patients. However, in recent years several cases of acute pulmonary edema due to the application of neostigmine have been reported.…”
Section: Discussionmentioning
confidence: 99%